Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves first treatment for chronic rhinosinusitis with nasal polyps

SILVER SPRING, Md., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps," said Sally Seymour, M.D., Director of the Division of Pulmonary, Allergy and Rheumatology Products in the FDA's Center for Drug Evaluation and Research. "Dupixent provides an important treatment option for patients whose nasal polyps are not adequately controlled with intranasal steroids. It also reduces the need for nasal polyp surgery and oral steroids." 

Dupixent is given by injection. The efficacy and safety of Dupixent were established in two studies with 724 patients, 18 years and older with chronic rhinosinusitis with nasal polyps who were symptomatic despite taking intranasal corticosteroids. Patients who received Dupixent had statistically significant reductions in their nasal polyp size and nasal congestion compared to the placebo group. Patients taking Dupixent also reported an increased ability to smell and required less nasal polyp surgery and oral steroids.

Dupixent may cause serious allergic reactions and eye problems, such as inflammation of the eye (conjunctivitis) and inflammation of the cornea (keratitis). If patients experience new or worsening eye symptoms, such as redness, itching, pain or visual changes, they should consult their health care professional. The most common side effects reported include injection site reactions as well as eye and eyelid inflammation, which included redness, swelling and itching. Patients receiving Dupixent should avoid receiving live vaccines.

Dupixent was originally approved in 2017 for patients 12 and older with eczema that is not controlled adequately by topical therapies or when those therapies are not advisable. In 2018, Dupixent was approved as an add-on maintenance treatment for patients 12 years and older with moderate-to-severe eosinophilic asthma or with oral corticosteroid-dependent asthma.

The FDA granted this application Priority Review. The approval of Dupixent was granted to Regeneron Pharmaceuticals.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Nathan Arnold, 301-796-6248, nathan.arnold@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

These press releases may also interest you

at 09:05
HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform...

at 09:05
Generex Biotechnology Corporation today announced that Richard Purcell, the company's Executive Vice President of Research & Development conducted an interview with Mike Elliott of CEO Roadshow, which is available at:...

at 09:00
The Oncology Institute of Hope and Innovation welcomes Lianping Weng M.D., to their team of specialists. Dr. Liangping Weng graduated with his Doctor of Medicine from Wannan Medical College in Wuhu, Anhui, China. He completed his residency in...

at 09:00
Abbott today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinitytm Deep Brain Stimulation (DBS) system to include targeting of an area of the brain called the...

at 09:00
The global market for Marine Biotechnology is projected to reach US$6.1 billion by 2025, driven by the rise of "circular economy" as the blueprint for a new sustainable economy in the 21st century. Against the backdrop of this age of "Sustainalism",...

at 09:00
PM360, a leading health-marketing industry trade magazine, announced the winners of their annual Pharma Choice Awards, which recognize the best healthcare creative campaigns and initiatives in 15 categories: Animal Health, App, Consumer Website,...

News published on 26 june 2019 at 16:36 and distributed by: